Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.

The global Pulmonary Hypertension Drug market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Pulmonary Hypertension Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pulmonary Hypertension Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Pulmonary Hypertension Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Pulmonary Hypertension Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc.
Abbott Laboratories
Boehringer Ingelheim GmbH
AstraZeneca plc
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries Ltd.
Vectura Group plc
Pfizer Inc.

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists
Phosphodiesterase-5 Inhibitors
Soluble Guanylate Cyclase Stimulators

Segment by Application
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)